Payment overview · 2025
General Payments
$857.17
43 reported records · 14 companies
Healthcare provider profile · identity verified
Jason Paul Gamble, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · BESSEMER, AL · NPI 1396724613
Verified facts
What the public records show
CMS Open Payments records show Jason Paul Gamble, M.D. received $857.17 in general payments during 2025 across 43 reported records.
Insmed, Inc. accounted for 18.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Insmed, Inc. | Unresolved — no canonical attribution shown | $160.84 | 18.8% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $158.35 | 18.5% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $144.99 | 16.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $111.17 | 13.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.26 | 8.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.47 | 6.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.68 | 3.7% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.92 | 2.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.04 | 2.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.97 | 2.1% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.88 | 2.1% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $16.27 | 1.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.48 | 1.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.85 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $857.17 | 43 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $160.84 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $158.35 | 7 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $111.17 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $103.39 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.47 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $41.60 | 2 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $37.00 | 2 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $14.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 95 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
95 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 386 | 108 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 286 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 228 | 64 |
| Levothyroxine Sodium | Levothyroxine Sodium | 228 | 55 |
| Gabapentin | Gabapentin | 219 | 50 |
| Losartan Potassium | Losartan Potassium | 205 | 67 |
| Metoprolol Succinate | Metoprolol Succinate | 184 | 56 |
| Potassium Chloride | Potassium Chloride | 171 | 45 |
| Furosemide | Furosemide | 142 | 42 |
| Duloxetine Hcl | Duloxetine Hcl | 132 | 24 |
| Alendronate Sodium | Alendronate Sodium | 131 | 30 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 48 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 102 | 22 |
| Lorazepam | Lorazepam | 98 | 23 |
| Omeprazole | Omeprazole | 97 | 28 |
| Farxiga | Dapagliflozin Propanediol | 96 | 17 |
| Eliquis | Apixaban | 95 | 19 |
| Celecoxib | Celecoxib | 92 | 34 |
| Montelukast Sodium | Montelukast Sodium | 87 | 30 |
| Allopurinol | Allopurinol | 82 | 24 |
| Trazodone Hcl | Trazodone Hcl | 81 | 20 |
| Pregabalin | Pregabalin | 80 | 12 |
| Carvedilol | Carvedilol | 79 | 21 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 21 |
| Clonazepam | Clonazepam | 78 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 77 | 13 |
| Methylprednisolone | Methylprednisolone | 76 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 74 | 23 |
| Metformin Hcl | Metformin Hcl | 72 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 71 | 23 |
| Famotidine | Famotidine | 70 | 27 |
| Ozempic | Semaglutide | 69 | 11 |
| Tramadol Hcl | Tramadol Hcl | 66 | 22 |
| Alprazolam | Alprazolam | 61 | 14 |
| Metformin Hcl Er | Metformin Hcl | 61 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 60 | 21 |
| Linzess | Linaclotide | 60 | 15 |
| Sertraline Hcl | Sertraline Hcl | 60 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 59 | 18 |
| Lisinopril | Lisinopril | 58 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 19 |
| Methocarbamol | Methocarbamol | 57 | 25 |
| Cefdinir | Cefdinir | 56 | 50 |
| Donepezil Hcl | Donepezil Hcl | 56 | 14 |
| Meloxicam | Meloxicam | 53 | 21 |
| Prednisone | Prednisone | 51 | 41 |
| Hydrochlorothiazide | Hydrochlorothiazide | 50 | 14 |
| Glimepiride | Glimepiride | 48 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 46 | 13 |
| Ezetimibe | Ezetimibe | 45 | 15 |
| Tradjenta | Linagliptin | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 40 | suppressed |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Azithromycin | Azithromycin | 36 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | 11 |
| Simvastatin | Simvastatin | 34 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 33 | suppressed |
| Chlorthalidone | Chlorthalidone | 32 | suppressed |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 30 | suppressed |
| Jardiance | Empagliflozin | 30 | suppressed |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 22 |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 24 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Estradiol | Estradiol | 23 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 22 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 18 |
| Cilostazol | Cilostazol | 19 | suppressed |
| Januvia | Sitagliptin Phosphate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Metronidazole | Metronidazole | 18 | 14 |
| Torsemide | Torsemide | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 11 |
| Ondansetron Odt | Ondansetron | 17 | 11 |
| Terbinafine Hcl | Terbinafine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Colchicine | Colchicine | 16 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Cephalexin | Cephalexin | 14 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 13 | suppressed |
| Trulicity | Dulaglutide | 13 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Dofetilide | Dofetilide | 12 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $857.17 · 43 records | Insmed, Inc. | ABRYSVO, AREXVY, Arikayce, Auvelity, Brinsupri, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, General - Pain Management, KRYSTEXXA, MOUNJARO, NUCALA, Ozempic, PREVNAR 20, RELISTOR, SHINGRIX, Wegovy, YUPELRI, ZEVTERA | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error